Adamis Pharmaceuticals Corp. (OTCQB: ADMP) develops specialty pharmaceutical and biotechnology healing products for respiratory disease, allergy, oncology and immunology. Adamis Pharmaceuticals is developing low-cost, therapeutic alternatives for treating anaphylaxis, asthma, chronic obstructive pulmonary disease and allergic rhinitis and has a novel, cell-based therapeutic cancer vaccine and three drug candidates for treating prostate cancer. For more information, visit the company’s website at www.adamispharmaceuticals.com.